Veraxa Biotech AG

VRXAHealthcare·Biotechnology·Switzerland·Micro·NASD·Nov 11 • 2:15 PM ET

1.25+0.18 (16.82%)

2026-11-11 20:16 CET

Market cap

158.07 USD m

Revenue, TTM

0.00 USD m

Net income, TTM

6.74 USD m

Free cash flow, TTM

-0.41 USD m

EPS diluted, TTM

0.21

P/E

5.84

Compare

Price

VRXA against its 20, 50 and 200-day averages

2050200

95.4% under the 52-week high of 27.36 on 11 Jun 2026. 52-week low 0.90 on 6 Nov 2026. Last 15 sessions, 47.8% high to low

Profile

VRXA

52-week range, 1% of the way up

0.9027.36

Veraxa Biotech Holding AG engages in operating an oncology-focused biotechnology company, which is the Veraxa Biotech AG (Company). The Company focuses on the development of novel antibody-based drug platforms for the treatment of cancer. The company was founded on June 25, 2025 and is headquartered in Zurich, Switzerland.

Employees	3
IPO	Sep 30, 2024
Beta	0.22
ATR, 14d	0.13
Rel volume	1.16
Short float	0.25%
Insider own	75.07%
Inst own	0.19%

Snapshot

6 groups

Valuation

Index	-
Market Cap	184.66M
Enterprise Value	184.63M
Income	6.74M
Sales	0.00M
Book/sh	-2.25
Cash/sh	0.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	3
IPO	Sep 30, 2024

Ratios

P/E	5.84
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	6155.37
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.00
Current Ratio	0.00
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

Earnings

EPS (ttm)	0.21
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	2.24%
Sales Y/Y TTM	-
EPS Q/Q	-91.03%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Ownership

Insider Own	75.07%
Insider Trans	0.09%
Inst Own	0.19%
Inst Trans	55.80%
ROA	2.52%
ROE	5.72%
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	20.53%
SMA50	0.82%
SMA200	-81.02%
Trades	-

Technical

Shs Outstand	147.73M
Shs Float	36.83M
Short Float	0.25%
Short Ratio	0.35
Short Interest	0.09M
52W High	27.36 -95.43%
52W Low	0.90 38.89%
Volatility	10.90% 10.56%
ATR (14)	0.13
RSI (14)	58.87
Beta	0.22
Rel Volume	1.16
Avg Volume	259.06K
Volume	223,304

Performance

Perf Week	31.58%
Perf Month	4.17%
Perf Quarter	-33.86%
Perf Half Y	-88.24%
Perf YTD	-88.28%
Perf Year	-88.11%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	1.07
Price	1.25
Change %	16.82%

Peers

Mkt cap

Ticker	Company	Mkt cap
STRO	Sutro Biopharma Inc	169.16M
PYXS	Pyxis Oncology Inc	196.50M
CTMX	CytomX Therapeutics Inc	465.44M
ZYME	Zymeworks BC Inc	2.02B
BCYC	Bicycle Therapeutics Plc ADR	186.57M
ADCT	Adc Therapeutics SA	203.63M
ADAG	Adagene Inc ADR	149.05M
XLO	Xilio Therapeutics Inc	55.74M
BOLT	Bolt Biotherapeutics Inc	12.14M
IMNM	Immunome Inc	2.26B

Ticker

Company

Mkt cap

STRO

Sutro Biopharma Inc

169.16M

PYXS

Pyxis Oncology Inc

196.50M

CTMX

CytomX Therapeutics Inc

465.44M

ZYME

Zymeworks BC Inc

2.02B

BCYC

Bicycle Therapeutics Plc ADR

186.57M

ADCT

Adc Therapeutics SA

203.63M

ADAG

Adagene Inc ADR

149.05M

XLO

Xilio Therapeutics Inc

55.74M

BOLT

Bolt Biotherapeutics Inc

12.14M

IMNM

Immunome Inc

2.26B

Insider trading

5 filings

Insider	Relationship	Date	Transaction	Cost	Shares	Value	Total held	Form
Gruninger Marc	Director	Oct 28 '26	Buy	1.00	9,133	9,133	10,000	Oct 29 04:52 PM
Gruninger Marc	Director	Oct 27 '26	Buy	0.98	867	850	867	Oct 29 04:52 PM
Ziegler Christoph Samuel	Director	Oct 20 '26	Buy	1.09	30,000	32,700	37,932	Oct 21 04:10 PM
Baumann Oliver Rolf	Director	Aug 27 '26	Buy	1.50	50,000	75,000	5,773,618	Aug 31 04:10 PM
Antz Christoph Rudiger	Chief Executive Officer	Aug 27 '26	Buy	1.53	5,000	7,650	5,000	Aug 31 04:10 PM

Held by

AUM

Ticker	Company	AUM
ONEQ	Fidelity Nasdaq Composite Index ETF	AUM: 10.35B

Ticker

Company

AUM

ONEQ

Fidelity Nasdaq Composite Index ETF

AUM: 10.35B

News

latest 14 of 106

Oct-21-26 03:00PMVERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline (NewMediaWire)
Oct-13-26 03:30PMVERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress (NewMediaWire) +5.26%
07:00AMVERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC-ADC Technology at World ADC Congress (GlobeNewswire)
Oct-07-26 03:00PMVERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing (NewMediaWire) +11.11%
09:29AMVeraxa Biotech stock gains on FDA-aligned testing strategy (Investing.com)
09:09AMMicro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It? (Barrons.com)
07:00AMVERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy (GlobeNewswire)
Sep-24-26 03:38PMVERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress (NewMediaWire)
Sep-22-26 02:30PMVERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase (NewMediaWire)
Sep-18-26 03:30PMVERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline (NewMediaWire)
Sep-16-26 03:00PMVERAXA Biotech (VRXA) Building a New Approach to Precision Cancer Therapy (NewMediaWire)
Sep-09-26 11:46AMVERAXA Biotech Designates Raju Willener as CFO (Exec Edge)
Sep-08-26 02:34PMVERAXA Biotech (VRXA) Appoints Raju Willener as Chief Financial Officer (NewMediaWire) -9.09%
Sep-04-26 07:00AMVERAXA Biotech Appoints Raju Willener as Chief Financial Officer (GlobeNewswire) +15.03%

Key figures

Revenue, TTM	0.00
Net income, TTM	6.74
EPS diluted, TTM	0.21
EBIT, TTM	-3.71
Free cash flow, TTM	-0.41
Gross margin	-%
Operating margin	-%
Net margin	-%
Market cap	158.07
P/E	5.84
Sales Y/Y, TTM	-

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
No quarterly earnings.

Period

Reported

EPS act

EPS est

EPS rep

Sales act

Sales est

Analysts

No quarterly earnings.

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
No annual earnings.

Period

EPS act

EPS est

EPS rep

Sales act

Sales est

No annual earnings.

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
No estimate revisions.

Period

Type

Date

Estimates

Down

Mean

Low

High

No estimate revisions.

Estimate history

Period	2023	2024	2025	TTM
EPS, annual	0	0.131	0.284	0.2142
EPS, quarterly	-0.002	-0.002	0.042	0.092	0.077	0.079	0.075	0.054	0.007
Period	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Sales, annual	0	0	0	0
Period	2023	2024	2025	TTM
Sales, quarterly	0	0	0	0	0	0	0	0	0
Period	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Shares, annual	31.625	31.625	31.625	6.408
Period	2023	2024	2025	MRQ
Shares, quarterly	31.625	31.625	31.625	31.625	31.625	31.625	31.625	31.625	6.408
Period	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY
Total Revenue	0.00	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
Selling, General and Administrative Excl. Other	3.71	1.79	0.70	0.01
Other Operating Expense	0.00	0.00	0.00	0.00
Operating Income	-3.71	-1.79	-0.70	-0.01
Interest Expense	0.00	0.00	0.00	0.00
Unusual Expense	-	0.00	-0.16	0.00
Net Income Before Taxes	6.74	8.99	4.14	-0.01
Income Taxes	0.00	0.00	0.00	0.00
Consolidated Net Income	6.74	8.99	4.14	-0.01
Net Income From Continuing Operations	6.74	8.99	4.14	-0.01
Net Income	6.74	8.99	4.14	-0.01
EPS (Recurring)	0.26	0.28	0.13	-0.00
EPS (Basic, Before Extraordinaries)	0.21	0.28	0.13	-0.00
EPS (Diluted)	0.21	0.28	0.13	-0.00
EBITDA	-3.71	-1.79	-0.70	-0.01
Non-Operating Income (Expense)	10.45	10.77	4.69	0.00
Other After Tax Adjustments	0.00	0.00	0.00	0.00
Price To Earnings Ratio	5.00	5.00	-	-
Shares Outstanding	6.41	31.62	31.62	31.62
Market Capitalization	158.07	158.07	316.88	316.88

Income statement, quarterly

Currency USD, millions
Metric	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling, General and Administrative Excl. Other	2.19	0.87	0.41	0.24	0.27	0.07	0.53	0.05
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-2.19	-0.87	-0.41	-0.24	-0.27	-0.07	-0.53	-0.05
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Unusual Expense	0.00	-	0.00	0.00	0.00	-0.06	-0.10	0.00
Net Income Before Taxes	0.18	1.71	2.36	2.49	2.43	2.92	1.32	-0.05
Income Taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Consolidated Net Income	0.18	1.71	2.36	2.49	2.43	2.92	1.32	-0.05
Net Income From Continuing Operations	0.18	1.71	2.36	2.49	2.43	2.92	1.32	-0.05
Net Income	0.18	1.71	2.36	2.49	2.43	2.92	1.32	-0.05
EPS (Recurring)	0.01	0.05	0.07	0.08	0.08	0.09	0.04	-0.00
EPS (Basic, Before Extraordinaries)	0.01	0.05	0.07	0.08	0.08	0.09	0.04	-0.00
EPS (Diluted)	0.01	0.05	0.07	0.08	0.08	0.09	0.04	-0.00
EBITDA	-2.19	-0.87	-0.41	-0.24	-0.27	-0.07	-0.53	-0.05
Non-Operating Income (Expense)	2.37	2.58	2.76	2.73	2.70	2.93	1.75	0.00
Other After Tax Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price To Earnings Ratio	5.00	33.06	36.20	49.58	-	-	-	-
Shares Outstanding	6.41	31.62	31.62	31.62	31.62	31.62	31.62	31.62
Market Capitalization	158.07	337.44	331.92	328.48	321.94	316.88	282.40	-

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY	2023FY
Cash & Short Term Investments	0.18	0.67	0.00
Short Term Receivables	0.00	0.00	0.00
Inventories	0.00	0.00	0.00
Other Current Assets	0.01	0.04	0.00
Total Current Assets	0.19	0.71	0.00
Net Property, Plant & Equipment	0.00	0.00	0.00
Total Investments and Advances	269.86	259.10	0.00
Intangible Assets	0.00	0.00	0.00
Other Assets	0.00	0.00	0.07
Total Assets	270.06	259.81	0.07
Short Term Debt Incl. Current Port. of LT Debt	0.00	0.00	0.00
Accounts Payable	0.00	0.00	0.00
Other Current Liabilities	1.29	0.04	0.08
Total Current Liabilities	1.29	0.04	0.08
Long Term Debt	0.00	0.00	0.00
Provision for Risks Charges	0.00	0.00	0.00
Other Liabilities	12.04	12.04	0.00
Total Liabilities	13.34	12.08	0.08
Non-Equity Reserves	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00
Common Equity	256.72	247.73	-0.01
Total Shareholders Equity	256.72	247.73	-0.01
Accumulated Minority Interest	0.00	0.00	0.00
Total Equity	256.72	247.73	-0.01
Total Liabilities & Stockholders Equity	270.06	259.81	0.07
Book Value Per Share	8.12	7.83	-0.00
Tangible Book Value Per Share	8.12	7.83	-0.00
Full-Time Employees	3	3	3
Price to Book Ratio	-0.47	1.29	1.29
Return on Assets	3.39	3.19	-
Return on Equity	3.56	3.34	-
Return on Invested Capital	3.50	1.67	-
Quick Ratio	0.15	18.28	0.00
Current Ratio	0.15	18.28	0.00

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY
Net Income	6.74	8.99	4.14	-0.01
Other Funds (Non Cash)	-10.44	-10.76	-4.83	0.00
Funds from Operations	-3.71	-1.77	-0.69	-0.01
Extraordinary Item	0.00	0.00	0.00	0.00
Changes in Working Capital	3.30	1.29	-0.01	0.01
Cash from Operating Activities	-0.41	-0.49	-0.70	0.00
Capital Expenditures	0.00	0.00	0.00	0.00
Net Assets From Acquisitions	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	0.00	0.00	-254.26	0.00
Purchase of Investments	0.00	0.00	-254.26	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00
Cash from Investing Activities	0.00	0.00	-254.26	0.00
Cash Dividends Paid	0.00	0.00	0.00	0.00
Change in Capital Stock	0.00	0.00	255.69	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	0.00	0.00	255.69	0.00
Proceedsfrom Stock Options	0.00	0.00	255.69	0.00
Issuance or Reduction of Debt, Net	0.00	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	-0.05	0.00
Other Financing Activities Uses	0.00	0.00	-0.05	0.00
Cash from Financing Activities	0.00	0.00	255.64	0.00
Net Change in Cash	-0.41	-0.49	0.67	0.00
Free Cash Flow	-0.41	-0.49	-0.70	0.00
Preferred Dividends (Cash Flow)	-	0.00	0.00	0.00
Deferred Taxes & Investment Tax Credit	-	0.00	0.00	0.00

Balance sheet, quarterly

Currency USD, millions
Metric	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4
Cash & Short Term Investments	0.03	0.18	0.25	0.09	0.45	0.67
Short Term Receivables	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	0.01	0.01	0.01	0.21	0.06	0.04
Total Current Assets	0.04	0.19	0.26	0.30	0.50	0.71
Net Property, Plant & Equipment	0.00	0.00	0.00	0.00	0.00	0.00
Total Investments and Advances	272.24	269.86	267.28	264.52	261.79	259.10
Intangible Assets	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	0.00	0.00	0.00	0.00	0.00	0.00
Total Assets	272.28	270.06	267.55	264.82	262.29	259.81
Short Term Debt Incl. Current Port. of LT Debt	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Liabilities	274.68	1.29	0.49	0.13	0.09	0.04
Total Current Liabilities	274.68	1.29	0.49	0.13	0.09	0.04
Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Provision for Risks Charges	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	12.04	12.04	12.04	12.04	12.04	12.04
Total Liabilities	286.73	13.34	12.54	12.17	12.13	12.08
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	-14.45	256.72	255.01	252.65	250.16	247.73
Total Shareholders Equity	-14.45	256.72	255.01	252.65	250.16	247.73
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	-14.45	256.72	255.01	252.65	250.16	247.73
Total Liabilities & Stockholders Equity	272.28	270.06	267.55	264.82	262.29	259.81
Book Value Per Share	-2.25	8.12	8.06	7.99	7.91	7.83
Tangible Book Value Per Share	-2.25	8.12	8.06	7.99	7.91	7.83
Full-Time Employees	-	3	-	-	-	3
Price to Book Ratio	-0.47	1.32	1.31	1.31	1.32	1.29
Return on Assets	2.52	3.39	3.89	6.91	5.05	-
Return on Equity	5.72	3.56	4.08	7.26	5.30	-
Return on Invested Capital	-	0.66	0.92	0.99	0.97	1.18
Quick Ratio	0.00	0.15	0.54	2.41	5.81	18.28
Current Ratio	0.00	0.15	0.54	2.41	5.81	18.28

Cash flow, quarterly

Currency USD, millions
Metric	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4
Net Income	0.18	1.71	2.36	2.49	2.43	2.92
Other Funds (Non Cash)	-2.37	-2.58	-2.76	-2.73	-2.69	-3.00
Funds from Operations	-2.19	-0.87	-0.40	-0.24	-0.26	-0.08
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	2.04	0.80	0.56	-0.12	0.04	-0.01
Cash from Operating Activities	-0.15	-0.07	0.16	-0.35	-0.22	-0.09
Capital Expenditures	0.00	0.00	0.00	0.00	0.00	0.00
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activities	0.00	0.00	0.00	0.00	0.00	0.00
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	0.00	0.00	0.00	0.00	0.00	0.05
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.05
Proceedsfrom Stock Options	0.00	0.00	0.00	0.00	0.00	0.05
Issuance or Reduction of Debt, Net	0.00	0.00	0.00	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.00	0.00	0.00	-0.05
Other Financing Activities Uses	0.00	0.00	0.00	0.00	0.00	-0.05
Cash from Financing Activities	0.00	0.00	0.00	0.00	0.00	-1E-06
Net Change in Cash	-0.15	-0.07	0.16	-0.35	-0.22	-0.09
Free Cash Flow	-0.15	-0.07	0.16	-0.35	-0.22	-0.09

Revenue breakdown

Revenue split	-

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	0.25%	0.1M	36.8M	256.71K
2026-10-15	0.29%	0.1M	36.8M	283.79K
2026-09-30	0.64%	0.2M	36.8M	487.38K
2026-09-15	0.57%	0.2M	36.8M	575.50K
2026-08-31	0.55%	0.2M	36.8M	484.70K
2026-08-14	0.89%	0.4M	42.6M	456.89K
2026-07-31	5.25%	0.4M	7.6M	441.24K
2026-07-15	3.16%	0.2M	7.6M	388.31K
2026-06-30	1.73%	0.1M	7.6M	103.31K
2026-06-15	0.04%	0.0M	25.3M	16.48K

Option chain

expiry 2026-11-11

Type	Strike	Bid	Ask	Last	IV	Open int	Volume	Delta	Theta	Vega
No option chain for this symbol.

Type

Strike

Bid

Ask

Last

Open int

Volume

Delta

Theta

Vega

No option chain for this symbol.

Latest SEC filings

Filed	Form	Description	Period	Link
2026-10-29	4	Statement of changes in beneficial ownership of securities	2026-10-27	SEC
2026-10-21	4	Statement of changes in beneficial ownership of securities	2026-10-20	SEC
2026-10-15	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-10-15	SEC
2026-09-14	3	Initial statement of beneficial ownership of securities	2026-09-01	SEC
2026-09-04	424B3			SEC
2026-09-04	424B3			SEC
2026-09-04	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-09-04	SEC
2026-08-31	4	Statement of changes in beneficial ownership of securities	2026-08-27	SEC
2026-08-31	4	Statement of changes in beneficial ownership of securities	2026-08-27	SEC
2026-08-24	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-08-24	SEC
2026-08-20	3	Initial statement of beneficial ownership of securities	2026-07-10	SEC
2026-08-13	SCHEDULE 13G/A			SEC
2026-08-10	424B5			SEC
2026-08-10	424B5			SEC
2026-08-06	EFFECT	Effectiveness filing by commission order		SEC
2026-08-06	EFFECT	Effectiveness filing by commission order		SEC
2026-08-05	F-1/A			SEC
2026-08-05	F-1/A			SEC
2026-07-31	F-1	Registration statement for certain foreign private issuers		SEC
2026-07-31	F-1	Registration statement for certain foreign private issuers		SEC
2026-07-31	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-07-31	SEC
2026-07-27	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-07-27	SEC
2026-07-27	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-07-27	SEC
2026-06-18	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-06-18	SEC
2026-06-16	SCHEDULE 13D			SEC
2026-06-16	SCHEDULE 13D			SEC
2026-06-16	20-F	Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.	2025-12-31	SEC
2026-06-15	SCHEDULE 13D			SEC
2026-06-15	SCHEDULE 13D			SEC
2026-06-11	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-06-10	SEC

Insider activity by month

Month	Bought	Buys
2026-11	0	0
2026-10	42.68K	3
2026-09	0	0
2026-08	82.65K	2
2026-07	0	0
2026-06	0	0
2026-05	0	0
2026-04	0	0
2026-03	0	0
2026-02	0	0
2026-01	0	0
2025-12	0	0
2025-11	0	0

Institutional holders

Manager	% owned
PICTON MAHONEY ASSET MANAGEMENT	0.55%
GEODE CAPITAL MANAGEMENT, LLC	0.06%
HRT FINANCIAL LP	0.06%
UBS Group AG	0.05%
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.03%
JPMORGAN CHASE & CO	0.00%
WOLVERINE ASSET MANAGEMENT LLC	0.00%
Caitong International Asset Management Co., Ltd	0.00%

Funds

Fund	% owned
Fidelity Nasdaq Composite Index Fund	0.04%
JNL Multi-Manager Alternative Fund	0.02%
Fidelity Nasdaq Composite Index ETF	0.02%
JNL/Westchester Capital Event Driven Fund	0.01%

OakChart. VRXA. Cached 15 minutes.

Some panels did not load: ratings.